FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

2 QSR Violations at Qinjiang Kingphar Medical

FDA warns Chinas Qinjiang Kingphar Medical Material Co. about Quality System violations in its production of several medical devices.

latest-news-card-1
Human Drugs

FDA Drug Onshoring Policies Could Work: Attorneys

Two Hyman, Phelps & McNamara attorneys report on the optimistic tone at a recent FDA public meeting on increasing U.S. drug manufacturing.

latest-news-card-1
Medical Devices

Multiple Violations Seen in Contec Medical Inspection

FDA warns Chinas Contec Medical Systems about Quality System and Medical Device Reporting violations in its manufacturing of several medical devices.

latest-news-card-1
Biologics

FDA Signals Pragmatic Push to Ease Biosimilar Development

FDA Office of Therapeutic Biologics and Biosimilars director Sarah Yim says the agency is focused on making biosimilar development faster and more pre...

latest-news-card-1
Biologics

BioMarins sBLA for Palynziq for Expanded Use

FDA accepts for priority review a BioMarin Pharmaceutical supplemental BLA for Palynziq (pegvaliase-pqpz) to expand the therapys use for treating adol...

latest-news-card-1
Human Drugs

Rare Cancer Seamless Clinical Trials

A Friends of Cancer Research working group white paper makes the case for seamless clinical trials for rare cancers.

latest-news-card-1
Biologics

FDA Aims to Cut Comparative Efficacy Studies for Biosimilars

FDA proposes a major shift in how biosimilars are evaluated, signaling that many products may no longer need traditional comparative clinical efficacy...

latest-news-card-1
Human Drugs

Revolution Medicines Wins Orphan Drug Status

FDA grants Revolution Medicines an orphan drug designation for its investigational therapy daraxonrasib for treating pancreatic cancer.

latest-news-card-1
Biologics

Regeneron Gets Complete Response on Eylea sBLA

FDA sends Regeneron a complete response letter for its pre-filled Eylea HD syringe supplemental BLA, citing unresolved inspection findings at third-pa...